MedDataX Logo

Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers

NCT ID: NCT01675258

Last Updated: 2012-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across the world. Diagnosis in the early stages improves survival rates. Up to now, these cancers are mostly diagnosed only at later stages of the disease's course through histoimmune staining and molecular biology processes on the tissues biopsied from the gastrointestinal system under invasive diagnostic procedures of colonoscopy.

Oral fluid presents a large protein complexity and has been recently used as a diagnostic biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal cancers. Proteomic technologies provide the tools needed to discover and identify disease-associated biomarkers.

The aim of the present study is to identify salivary bio-markers in patients suffering from colorectal cancers.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer Colorectal Cancer and Pre-cancer Polyps Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control

Healthy adults above the age of 18 years

Salivary samples

Intervention Type OTHER

Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.

Study

Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer

Salivary samples

Intervention Type OTHER

Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Salivary samples

Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Salivary Analysis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has not yet started treatment for the identified cancer

Exclusion Criteria

* medically compromised patients
* congenital syndromes
* being treated with radiotherapy or chemotherapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hadassah Medical Organization

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Moti Moskovitz, DMD, PhD

Role: PRINCIPAL_INVESTIGATOR

Hadassah Medical Organization

Eyal Shtayer, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah Medical Organization

Avi Levin, MD

Role: PRINCIPAL_INVESTIGATOR

Hadassah Medical Organization

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hadassah Medical Organization

Jerusalem, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hadas Lemberg, PhD

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, Chia D, Wong DT. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology. 2010 Mar;138(3):949-57.e1-7. doi: 10.1053/j.gastro.2009.11.010. Epub 2009 Nov 18.

Reference Type RESULT
PMID: 19931263 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSA003-HMO-CTIL

Identifier Type: -

Identifier Source: org_study_id